Rhythm Pharmaceuticals (RYTM) just turned heads with a one-two punch of major news. The company announced positive phase 3 results for its drug setmelanotide, targeting obesity caused by hypothalamic damage, and followed this up by submitting regulatory applications for label expansion. As if that were not enough, Rhythm also revealed it is pushing another promising candidate, bivamelagon, into phase 3 studies early next year. These updates send a clear message that Rhythm is stepping up its game in the competitive weight management space.
Over the past year, Rhythm shares have returned an impressive 88%, reinforcing optimism from investors and hinting at buzz around its expanding pipeline. The stock’s 51% climb in the past three months suggests momentum is building, likely fueled by this fresh batch of clinical and regulatory milestones. Compared to its long-term track record and recent financial growth, including a 44% bump in annual revenue and significant improvement in net income, Rhythm seems to be gaining traction at a critical time in the obesity treatment market.
With the stock powering higher on clinical good news and future possibilities, the crucial question is whether Rhythm’s current price leaves room for further gains or if the market is already factoring in the next leg of growth.
Advertisement
Most Popular Narrative: 14.6% Undervalued
The prevailing narrative suggests that Rhythm Pharmaceuticals is currently undervalued by a notable margin, despite recent share price momentum and high growth expectations.
Extension of intellectual property protection to 2034 for the lead asset and to 2040 and beyond for next-generation compounds, along with orphan drug exclusivity incentives in the U.S. and EU, create a multi-year window of strong pricing power and high net margins. These protections shield earnings from generic and biosimilar erosion.
How does Rhythm’s growth story stack up against analyst models? The narrative imagines a future where surging revenues, a radically different profit outlook, and premium valuation multiples converge. Want to see what drives such a bullish fair value? Find out which quantitative leaps underpin these high expectations for earnings and margins.
However, persistent operating losses and a heavy reliance on setmelanotide could create challenges for Rhythm’s path to profitability and dampen future optimism.
A different angle comes from comparing Rhythm’s price-to-sales ratio with the average for US biotechs. This suggests the stock trades at a rich premium versus its industry. Does this signal investors may be getting ahead of themselves?
Stay updated when valuation signals shift by adding Rhythm Pharmaceuticals to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.
Build Your Own Rhythm Pharmaceuticals Narrative
If you see the story playing out differently or want to dig deeper on your own, you can shape your own view in just a few minutes with Do it your way.
A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
Looking for more investment ideas?
If you want to step up your portfolio strategy, jump into fresh opportunities that others may be overlooking. Simply Wall Street’s expert-curated screens make it easy to find tomorrow’s winners today. Start now and you’ll never wonder what you missed.
Unlock the future of tech by tapping into the next wave of innovation leaders through our handpicked quantum computing stocks.
Accelerate your search for real value by pinpointing promising companies the market has overlooked with the help of undervalued stocks based on cash flows.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies
